Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, much progress has been made in defining the signal transduction pathways mediating the cellular response to genotoxic stress. Multiple pathways involving several distinct MAP kinases (ERK,
JNK
/SAPK, and p38/HOG1) as well as the
tumor suppressor protein p53
contribute to the response; the various pathways being differentially activated by particular genotoxic agents. Although both DNA damage and extranuclear events are important in initiating the response, recent evidence suggests the response is controlled primarily through events occurring at the plasma membrane, overlapping significantly with those important in initiating mitogenic responses. Attenuation of the responses appears to be largely controlled through feedback mechanisms involving gene products produced during the activation process.
...
PMID:Signaling events controlling the molecular response to genotoxic stress. 885 80
Deregulated overexpression of c-Myc (Myc) confers susceptibility to apoptosis in several cell types, but the molecular regulation of these processes has not been well established. Here we have characterized several molecular changes that may modulate Myc-dependent apoptosis. Ectopic overexpression of Myc in both Rat1 fibroblasts and human osteosarcoma cells causes a dramatic increase of cellular
p53 mRNA
and protein, and this induction of
p53
correlates with apoptosis triggered by withdrawal of serum. Stable transfection of a wild-type human
p53
gene into Myc-transformed cells further potentiates apoptosis. Anticancer agents vinblastine and nocodazole also induce apoptosis in Myc-transformed Rat1 fibroblasts but are cytostatic to the same cells without Myc overexpression. We demonstrate that induction of Myc-dependent apoptosis in these cells is specifically associated with an activation of p46 c-Jun N-terminal kinase/stress-activated protein kinase (
JNK
/SAPK) activity, whereas this
JNK
/SAPK activation is absent in stress-treated cells without Myc overexpression. Moreover, overexpression of the Mdm-2 gene in Rat1-myc cells significantly inhibits apoptosis induced by low serum but has little effect on apoptosis triggered by chemotherapeutic drugs. Interestingly, differential inhibition by Mdm-2 paralleled differential activation of p46
JNK
/SAPK. Thus, our data support a functional involvement of
p53
in Myc-dependent apoptosis and implicate potential regulatory roles for
JNK
/SAPK and Mdm-2 pathways in the regulation of apoptosis in Myc-transformed tumor cells.
...
PMID:Regulation of Myc-dependent apoptosis by p53, c-Jun N-terminal kinases/stress-activated protein kinases, and Mdm-2. 921 67
Normal fibroblasts are resistant to the cytotoxic action of tumor necrosis factor (TNF), but are rendered TNF-sensitive upon deregulation of c-Myc. To assess if oncoproteins induce the cytotoxic TNF activity by modulating TNF signaling, we investigated the TNF-elicited signaling responses in fibroblasts containing a conditionally active c-Myc protein. In association with cell death, c-Myc impaired TNF-induced activation of phospholipase A2,
JNK
protein kinase and cell survival-signaling-associated NF-kappaB transcription factor complex. The TNF-induced death of mouse primary fibroblasts expressing deregulated c-Myc was inhibited by transient overexpression of the p65 subunit of NF-kappaB, which increased NF-kappaB activity in the cells. Unlike other TNF-induced signals, TNF-induced accumulation of the wild-type
p53 mRNA
and protein was not inhibited by c-Myc. TNF, with c-Myc, induced apoptosis in mouse primary fibroblasts but only weakly in
p53
-deficient primary fibroblasts. The C-terminal domain of
p53
, which is a transacting dominant inhibitor of wild-type
p53
, failed to inhibit apoptosis by c-Myc and TNF, suggesting that the cell death was not dependent on the transcription-activating function of
p53
. Taken together, the present findings show that the cytotoxic activity of TNF towards oncoprotein-expressing cells involves
p53
and an impaired signaling for survival in such cells.
...
PMID:Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. 940 67
Genotoxic stress triggers signalling pathways that either mediate cell killing or protection of affected cells. While induction of
p53
is observed for most of the genotoxins, activation of MAPK/SAPK cascades is not a general response. The role of MAPK/SAPK activation on cell fate, seems to be dependent, in some systems, on the balanced response among both cascades. We have here examined the effect of cis and trans-DDP on the activation of ERK and
JNK
activities. While no significant induction of ERK was observed with the compounds, both of them are able to strongly activate
JNK
. Trans-DDP response is rapid and transient while the cis-DDP one is slow and persistent. In contrast with the observed nuclear translocation of
JNK
in response to U.V. light, none of the platinum compounds induces translocation, on the contrary, activation of
JNK
occurs in both the nuclear and cytoplasmic compartments. Inhibition of tyrosine phosphatases by orthovanadate pretreatment prolongs the time of
JNK
induction in response to both platinum compounds. The positive modulation of
JNK
activation correlates with an increase in toxicity that, for cis-DDP corresponds to a tenfold decrease in the IC50. A strong increase in MKP-1 levels was observed only in response to trans-DDP suggesting the involvement of this activity in the downregulation of
JNK
activity in response to this compound. Altogether the results suggest that the prolonged activation of
JNK
in response to cis-DDP contributes to cell death induction.
...
PMID:Cisplatin induces a persistent activation of JNK that is related to cell death. 948 43
In this study we elucidated the role of nonactive
JNK
in regulating
p53
stability. The amount of
p53
-
JNK
complex was inversely correlated with
p53
level. A peptide corresponding to the
JNK
binding site on
p53
efficiently blocked ubiquitination of
p53
. Similarly,
p53
lacking the
JNK
binding site exhibits a longer half-life than
p53
(wt). Outcompeting
JNK
association with
p53
increased the level of
p53
, whereas overexpression of a phosphorylation mutant form of
JNK
inhibited
p53
accumulation.
JNK
-
p53
and Mdm2-
p53
complexes were preferentially found in G0/G1 and S/G2M phases of the cell cycle, respectively. Altogether, these data indicate that
JNK
is an Mdm2-independent regulator of
p53
stability in nonstressed cells.
...
PMID:JNK targets p53 ubiquitination and degradation in nonstressed cells. 973 64
Naturally occurring sympathetic neuron death is the result of two apoptotic signaling events: one normally suppressed by NGF/TrkA survival signals, and a second activated by the p75 neurotrophin receptor. Here we demonstrate that the
p53 tumor suppressor protein
, likely as induced by the MEKK-
JNK
pathway, is an essential component of both of these apoptotic signaling cascades. In cultured neonatal sympathetic neurons,
p53 protein
levels are elevated in response to both NGF withdrawal and p75NTR activation. NGF withdrawal also results in elevation of a known p53 target, the apoptotic protein Bax. Functional ablation of
p53
using the adenovirus E1B55K protein inhibits neuronal apoptosis as induced by either NGF withdrawal or p75 activation. Direct stimulation of the MEKK-
JNK
pathway using activated MEKK1 has similar effects;
p53
and Bax are increased and the subsequent neuronal apoptosis can be rescued by E1B55K. Expression of
p53
in sympathetic neurons indicates that
p53
functions downstream of
JNK
and upstream of Bax. Finally, when
p53
levels are reduced or absent in p53+/- or
p53
-/- mice, naturally occurring sympathetic neuron death is inhibited. Thus,
p53
is an essential common component of two receptor-mediated signal transduction cascades that converge on the MEKK-
JNK
pathway to regulate the developmental death of sympathetic neurons.
...
PMID:p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. 985 60
The ATP/ubiquitin-dependent 26S proteasome is a central regulator of cell cycle progression and stress responses. While investigating the application of peptide aldehyde proteasome inhibitors to block signal-induced IkappaBalpha degradation in human LNCaP prostate carcinoma cells, we observed that persistent inhibition of proteasomal activity signals a potent cell death program. Biochemically, this program included substantial upregulation of PAR-4 (prostate apoptosis response-4), a putative pro-apoptotic effector protein and stabilization of c-jun protein, a potent pro-death effector in certain cells. We also observed modest downregulation of bcl-XL, a pro-survival effector protein. However, in contrast to some recent reports stable, high level, expression of functional bcl-2 protein in prostate carcinoma cells failed to signal protection against cell death induction by proteasome inhibitors. Also in disagreement to a recent report, no evidence was found for activation of the
JNK
stress kinase pathway. A role for
p53
, a protein regulated by the proteasome pathway, was ruled out, since comparable cell death induction by proteasome inhibitors occurred in PC-3 cells that do not express functional
p53 protein
. These data signify that the ubiquitin/proteasome pathway represents a potential therapeutic target for prostate cancers irrespective of bcl-2 expression or
p53
mutations.
...
PMID:Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. 987 95
The cellular response to DNA damage includes growth arrest and activation of DNA repair. Certain insights into how DNA damage is converted into intracellular signals that control the genotoxic stress response have been derived from the finding that the c-Abl protein tyrosine kinase is activated by ionizing radiation and other DNA-damaging agents. c-Abl associates with the DNA-dependent protein kinase (DNA-PK) and is activated by DNA-PK-dependent phosphorylation. The ataxia telangiectasia mutated (ATM) gene product also contributes to c-Abl activation. The demonstration that c-Abl binds to
p53
, induces the transactivation function of
p53
and activates p21 expression has supported involvement of c-Abl in regulation of the
p53
-dependent G1 arrest response. Interaction between c-Abl and the Rad51 protein has also provided support for involvement of c-Abl in recombinational repair of DNA strand breaks. Defects in G1 arrest and repair predispose to replication of damaged templates and, in the event of irreparable DNA lesions, induction of apoptosis. The available evidence indicates that c-Abl effects a proapoptotic function by a mechanism largely independent of
p53
. c-Abl also functions as an upstream effector of the proapoptotic
JNK
/SAPK and p38 MAPK pathways. In addition, c-Abl-dependent inhibition of PI 3-kinase contributes to the induction of apoptosis. The findings thus suggest that, in response to genotoxic stress, c-Abl functions in determining cell fate, that is growth arrest and repair or induction of apoptosis. The physiologic function of c-Abl may reside in control of the cellular response to DNA strand breaks that occur during DNA replication, genetic recombination and gene rearrangements.
...
PMID:Determination of cell fate by c-Abl activation in the response to DNA damage. 991 93
Induction of Fas expression by DNA-damaging agents is dependent on the expression of functional
p53
, and has been suggested to play an important role in apoptosis induction.
JNK
(c-Jun N-terminal kinase), which is capable of phosphorylating
p53
, is also involved in apoptotic signaling induced by various apoptotic stimuli. Here, we report that although Fas induction is closely linked to the expression of wild type
p53
, it is not correlated with
JNK
activation induced by apoptotic stimuli.
JNK
activation does not necessarily lead to Fas expression, even in cells containing wild type
p53
. In addition, Fas expression can be induced without significant
JNK
activation. Furthermore, induction of Fas expression is not sufficient for apoptosis induction; however, it may sensitize cells to Fas-ligation induced apoptosis.
...
PMID:Lack of correlation in JNK activation and p53-dependent Fas expression induced by apoptotic stimuli. 1008 Sep 43
EAT/mcl-1 showed increased expression during the differentiation of a multipotent human embryonic carcinoma cell line, NCR-G3, and of myeloblastic cells "ML-1," and has sequence similarity to Bcl-2. In this present study, we determined whether the apoptotic cell death induced by chemotherapeutic agents could be inhibited by EAT/mcl-1, as has been found with Bcl-2. Cells transfected with EAT/mcl-1 showed higher resistance to cis-diammine dichloroplatinum (II) (CDDP) and carboplatin compared with the parental line (10)1 and neomycin-resistance gene-transfected clone, (10)1/neo. There was, however, no difference in sensitivity to etoposide, N,N-bis-(2-chloroethyl)-N'-(3-hydroxypropyl) phosphordiamidic acid cyclic ester monohydrate, adriamycin or other chemotherapeutic agents tested. DNA fragmentation of the parental cells following treatment with CDDP and carboplatin was observed in a concentration-dependent manner. In contrast, cells transfected with EAT/mcl-1 did not show DNA fragmentation following treatment with the same concentration of these drugs. EAT/mcl-1 was capable of delaying the onset of
p53
-independent apoptosis, although it could not inhibit apoptosis completely. Since CDDP and carboplatin damage DNA and then activate c-abl and the
JNK
/SAPK pathway, EAT/mcl-1 may inhibit
p53
-independent apoptosis through a c-abl/
JNK
(SAPK)-dependent mechanism. EAT/mcl-1 has functional homology to Bcl-2 in that it can enhance cell viability under conditions which otherwise cause apoptosis and increase resistance to chemotherapeutic agents.
...
PMID:EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway. 1008 94
1
2
3
4
5
6
7
8
9
10
Next >>